Prospective Population Study on Candidemia in Spain

Fundacion SEIMC-GESIDA730 enrolled

Overview

The aim of this study is to describe the epidemiology of fungal blood infections in Spain (with emphasis on the incidence, fungal species distribution and antifungal susceptibility). The study is to be performed in five big cities which represent different geographic areas: Barcelona, Bilbao, Madrid, Sevilla and Valencia.

Study Type

OBSERVATIONAL

Enrollment

730

Conditions

Fungemia

Interventions

Non interventionOTHER

Non interventional study

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Fungal isolate obtained from blood sample Exclusion Criteria: * None

Locations (29)

Hospital del Mar

Outcomes

Primary Outcomes

Describe fungemia epidemiology in Spain

Recollection of demographic variables (age, gender and ethnic origin); clinical variables (background diseases, other coinfections, treatment received, etc) and microbiological information of the isolate.

Time frame: 1 year

Secondary Outcomes

Describe differences among cities and institutions

Analyze results in function of the city and hospital where the isolate was obtained (5 cities in Spain and 29 participating hospitals)

Time frame: 1 year

Definition of risk factors

Determine risk factors for: * bad clinical evolution * infection by a specific Candida species * fluconazole resistant isolate * fungemia persistency

Time frame: 1 year

Determination of the fungal isolates susceptibility to fluconazole, voriconazole, caspofungine, anidulafungine, micafungine and anfotericine B

Analysis of resistant strains percentage according to the threshold established by CLSI to each specific antifungal

Time frame: 1 year

Correlation between fungemia with a diminished susceptibility fungal strain and clinical evolution

Chi-square and Kaplan-Meier survival curves

Time frame: 1 year

Correlation between reference and commercial microbiological methods

Comparison of results when a reference or a commercial fungal identification and antifungal susceptibility method is used.

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.